Ziv‐aflibercept: A cost‐effective, off‐label, highly potent antagonist of vascular endothelial growth factor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Ziv‐aflibercept: A cost‐effective, off‐label, highly potent antagonist of vascular endothelial growth factor

Published:2019-12-20 Issue:5 Volume:98 Page:
ISSN:1755-375X
Container-title:Acta Ophthalmologica
language:en
Short-container-title:Acta Ophthalmol

Author:

Mansour Ahmad M.¹²^ORCID,Stewart Michael W.³,Farah Michel E.⁴,Mansour Hana A.¹²,Chhablani Jay⁵^ORCID

Affiliation:

1. Department of Ophthalmology American University of Beirut Beirut Lebanon

2. Department of Ophthalmology Rafik Hariri University Hospital Beirut Lebanon

3. Department of Ophthalmology Mayo Clinic Jacksonville FL USA

4. Department of Ophthalmology Federal University of São Paulo São Paulo Brazil

5. Department of Ophthalmology University of Pittsburgh Pittsburgh PA USA

Publisher

Wiley

Subject

Ophthalmology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/aos.14328

Reference62 articles.

1. Ziv‐aflibercept versus bevacizumab administration prior to diabetic vitrectomy: a randomized and controlled trial;Aleman I;Br J Ophthalmol,2019

2. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA

3. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR THE TREATMENT OF A PATIENT WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION

4. Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes

5. Comparison between the short-term outcomes of bevacizumab and ziv-aflibercept in the treatment of primary diabetic macular oedema

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetic Macular Edema Management: A Review of Anti-Vascular Endothelial Growth Factor (VEGF) Therapies;Cureus;2024-01-21

2. Therapeutic Fusion Proteins;The AAPS Journal;2023-11-30

3. Biosimilar to Biosimilar Anti-VEGF Switching for Retinal Diseases;Journal of VitreoRetinal Diseases;2023-09-29

4. The Biosimilar Paradox;Ophthalmology;2023-09

5. Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes;Journal of Ophthalmic and Vision Research;2023-04-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3